Crescent Biopharma (CBIO) Change in Receivables (2026)
Crescent Biopharma (CBIO) posted quarterly Change in Receivables of -$18.0 million for Q1 2026.
Crescent Biopharma (CBIO) Change in Receivables (2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Change in Receivables for 1 consecutive years, with -$18.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables changed N/A year-over-year to -$18.0 million; the TTM figure through Jun 2026 stood at -$18.0 million (changed N/A YoY), while the FY2025 annual figure was $18.0 million, changed N/A from the prior year.
- Change in Receivables steadied at -$18.0 million in Q1 2026 per CBIO's latest filing.
- Across five years, Change in Receivables topped out at -$18.0 million in Q1 2026 and bottomed at -$18.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.00 Mn |
| Mar 31, 2026 | -18.00 Mn |